COMMUNIQUÉS West-GlobeNewswire

European Patent Office Confirms Patent Protection for SOT201, SOTIO's Clinical-Stage Immunocytokine Showing Promising Anti-Tumor Activity
21/07/2026
PRAGUE and BASEL, Switzerland and BOSTON, July 21, 2026 (GLOBE NEWSWIRE) -- SOTIO Biotech , a clinical-stage biopharmaceutical company owned by PPF Group, today announced that the Boards of Appeal of the European Patent [...]
Calidi Biotherapeutics Provides Mid-Year Corporate Update and Future Key Value Drivers
21/07/2026
Company receives positive pre-IND feedback from US FDA for CLD-401, indicating agreement on its current development strategy as it advances towards a first-in-human study; targeting dosing first patient in Q1 2027 [...]
AssistRx and Medisafe Unite to Power Smarter, More Connected Patient Engagement
21/07/2026
Partnership delivers the real-time status updates and mobile-first engagement today's patients expect from therapy initiation through adherence ORLANDO, Fla., July 21, 2026 (GLOBE NEWSWIRE) -- AssistRx , the advanced [...]
Lonza and Engitix Announce License Agreement to Advance Targeted ADC Development
21/07/2026
Lonza grants Engitix target-specific license for GlycoConnect ® , HydraSpace ® and SYNtecan E™ linker-payload technologies for ADC development Collaboration enables innovative treatments by combining Lonza’s validated [...]
Vivex Biologics Launches VIA Linx™, a Novel Self-Assembling Synthetic Peptide Matrix, Expanding its Portfolio of Advanced Wound Care Solutions
21/07/2026
New molecular medical device joins Vivex's growing suite of allograft and advanced wound care technologies MIAMI, July 21, 2026 (GLOBE NEWSWIRE) -- Vivex Biologics, a leader in developing and delivering innovative [...]
Senseonics Holdings, Inc. Schedules Second Quarter 2026 Earnings Release and Conference Call for August 6, 2026 at 4:30 P.M. Eastern Time
21/07/2026
GERMANTOWN, Md., July 21, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on implantable Continuous Glucose Monitoring (CGM) Systems for people with diabetes, today [...]
Smith+Nephew introduces expanded enterprise ASC Solutions Strategy to support growth, performance and value-based care
21/07/2026
Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology company, today announced ASC Solutions: an expanded enterprise strategy for ambulatory surgery centers (ASCs) that takes a customer-centric approach to [...]
VYNE Therapeutics Announces 1-for-50 Reverse Stock Split and Provides Update Regarding Special Dividend in Connection with the Proposed Merger with Yarrow Bioscience
21/07/2026
Aggregate cash dividend of $17.3 million, or approximately $0.40242 per share NEW YORK, July 21, 2026 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that its Board of [...]
Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel
21/07/2026
WEST CHESTER, Pa., July 21, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological [...]
Vaxart to Participate in BTIG Biotechnology Conference 2026
21/07/2026
SOUTH SAN FRANCISCO, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery [...]
Rhythm Pharmaceuticals to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026
21/07/2026
BOSTON, July 21, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine [...]
Cadrenal Therapeutics Launches Partnering Process as Its Cardiac Acute Critical Care Assets Advance to Transaction Readiness Following Landmark ISTH Data Presentation
21/07/2026
Capital-efficient strategy focuses on differentiated therapies for cardiac pre- and post-operative critical care and orphan cardiovascular conditions Company is exploring development, licensing, and commercialization [...]
Jupiter Neurosciences (NASDAQ: JUNS) Signs Definitive Agreement for Exclusive U.S. Rights to ALA-002 in Transaction Valued at Up to $100 Million
21/07/2026
Transaction expands Jupiter into a dual clinical-stage CNS company by adding a differentiated FDA-designated Novel Chemical Entity alongside its Phase II Parkinson’s disease program JUPITER, FL, July 21, 2026 (GLOBE [...]
Applied Biologics Initiates Multi-Center Real-World Outcomes Study of XWRAP® Across Chronic Wound Types
21/07/2026
SCOTTSDALE, Ariz., July 21, 2026 (GLOBE NEWSWIRE) -- Applied Biologics, a biopharmaceutical company advancing novel biologic therapies for serious diseases with significant unmet medical needs, today announced the [...]
Akari Therapeutics Enters Strategic Research Collaboration with Whitehawk Therapeutics
21/07/2026
Collaboration will evaluate Akari's PH1 payload technology in combination with Whitehawk's TOP1i payload to generate potential future development opportunities TAMPA, Fla. and LONDON, July 21, 2026 (GLOBE NEWSWIRE) -- [...]
Kraig Biocraft Laboratories CEO Kim Thompson Featured in Just Style, a Leading Global Apparel Industry Trade Publication
21/07/2026
Interview Spotlights Company's Commercial-Scale Production Progress and Path to Transforming the Global Textile Industry ANN ARBOR, Mich., July 21, 2026 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB [...]
Axiom Biosciences Announces Intention to Become the First U.S. Biotech to List on the Hong Kong Stock Exchange
21/07/2026
SAN DIEGO, July 21, 2026 (GLOBE NEWSWIRE) -- Axiom Biosciences , a clinical-stage biotechnology company whose lead regenerative therapy produced positive early results in newborns with severe brain injury, today [...]
Tempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-T
21/07/2026
Tempest’s TPST-4003 is a next-generation in vivo CAR-T candidate combining proprietary CD7-targeted mRNA/LNP delivery with a dual-target CD19/BCMA CAR construct designed to enable broad B-cell lineage depletion and [...]
Agios Provides Update on Phase 2 Trial of Tebapivat in Sickle Cell Disease
21/07/2026
Hemoglobin response rates for tebapivat, a PK activator, were consistent with the class of medicine, but Phase 2 results did not establish a differentiated profile to support continued development in sickle cell disease [...]

Pages